98 Results for "

cyclin-dependent kinase inhibitors

" in MedChemExpress (MCE) Product Catalog:
Products (98)

98 Results for "cyclin-dependent kinase inhibitors" in MCE Product Catalog:

41
41 Publications Verification
Cat. No.: HY-12214A
CAS No.: 1263373-43-8
Purity:  99.60%
Target:  

CDK Apoptosis

Research Areas:  

Cancer

NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC50 of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC50 values of 0.584 μM, 0.706 μM, and 0.605 μM, respectively. NVP-2 induces cell apoptosis.
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-12467
CAS No.: 1338545-07-5
Purity:  99.74%
Target:  

TOPK CDK Apoptosis

Research Areas:  

Cancer

OTS964 hydrochloride is an orally active, high affinity and selective TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor with an IC50 of 28 nM . OTS964 hydrochloride is also a potent inhibitor of the cyclin-dependent kinase CDK11, which binds to CDK11B with a Kd of 40 nM .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-11009
CAS No.: 164658-13-3
Purity:  98.90%
Target:  

CDK PKC

Research Areas:  

Cancer

CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC50 values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-16462
CAS No.: 1263369-28-3
Target:  

CDK

Research Areas:  

Cancer

CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-114177
CAS No.: 2185857-97-8
Purity:  99.91%
Synonyms: PF-06873600
Target:  

CDK

Research Areas:  

Cancer

PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-137432
CAS No.: 1983983-41-0
Purity:  99.72%
Synonyms: BEY1107
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Avotaciclib (BEY1107) is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib can be used in the research of cancer such as pancreatic cancer and lung cancer .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-137432A
CAS No.: 1983984-01-5
Purity:  99.60%
Synonyms: BEY1107 trihydrochloride
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Avotaciclib (BEY1107) trihydrochloride is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib trihydrochloride can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib trihydrochloride can be used in the research of cancer such as pancreatic cancer and lung cancer .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-137432B
Purity:  99.75%
Synonyms: BEY1107 hydrochloride
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Avotaciclib (BEY1107) hydrochloride is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib hydrochloride can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib hydrochloride can be used in the research of cancer such as pancreatic cancer and lung cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-16559
CAS No.: 920113-03-7
Synonyms: P276-00
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13914
CAS No.: 1223498-69-8
Purity:  98.09%
Synonyms: BAY 1000394
Target:  

CDK

Research Areas:  

Cancer

Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC50s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-15275
CAS No.: 582315-72-8
Purity:  99.59%
BMS-265246 is a potent and selective cyclin-dependent kinase CDK1 and CDK2 inhibitor, with IC50 values of 6 and 9 nM, respectively. BMS-265246 inhibits CHI3L1 (chitinase 3-like-1) stimulation of ACE2 (angiotensin converting enzyme 2) and SPP (viral spike protein priming proteases). BMS-265246 can be used for ovarian cancer and COVID-19 research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-108136A
CAS No.: 145317-11-9
Purity:  98.90%
Synonyms: BIM-X hydrochloride; Ro31-8425 hydrochloride
Target:  

PKC CDK

Bisindolylmaleimide X hydrochloride(Ro 31-8425 hydrochloride, BIM-X hydrochloride) is a cell-penetrating PKC inhibitor. Bisindolylmaleimide X hydrochloride is a potent cyclin-dependent kinase 2 (CDK2) antagonist with an IC50 of 200 nM. Bisindolylmaleimide X hydrochloride inhibits the proliferation of CD4 T cells in vitro. Bisindolylmaleimide X hydrochloride inhibits eNOS-Ser1177 phosphorylation in human embryonic vein endothelial cells. Bisindolylmaleimide X hydrochloride can be used for research on the immune system and cardiovascular diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-141687
CAS No.: 22242-89-3
Purity:  99.97%
Target:  

CDK Apoptosis

Research Areas:  

Cancer

NSC 107512 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9). NSC 107512 is a class of sangivamycin-like molecules (SLM). NSC 107512 inhibits growth and induces apoptosis of multiple myeloma tumors .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-121035
CAS No.: 916440-85-2
Purity:  99.20%
Synonyms: 7-Bromoindirubin-3-Oxime
Target:  

CDK GSK-3

Research Areas:  

Neurological Disease

7BIO (7-Bromoindirubin-3-Oxime) is the derivate of indirubin. 7BIO (7-Bromoindirubin-3-Oxime) has inhibitory effects against cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3β (GSK3β). 7BIO (7-Bromoindirubin-3-Oxime) inhibits Aβ oligomer-induced neuroinflammation, synaptic impairments, tau hyper-phosphorylation, activation of astrocytes and microglia, and attenuates Aβ oligomer-induced cognitive impairments in mice [1].
loading...
    loading...
Cat. No.: HY-139254
CAS No.: 667463-82-3
Purity:  99.10%
Synonyms: IDR3O; I3O
Target:  

CDK GSK-3 JNK Wnt

Research Areas:  

Neurological Disease

Indirubin-3′-oxime (IDR3O), a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase(GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes .
loading...
    loading...
Cat. No.: HY-112358
CAS No.: 222036-17-1
Purity:  99.04%
Target:  

CDK

Research Areas:  

Neurological Disease Cancer

GW8510 is a potent cyclin-dependent kinase-2 (CDK2) inhibitor. GW8510 is also a ribonucleotide reductase M2 (RRM2) inhibitor. GW8510 exhibits neuroprotective and anticancer activities .
loading...
    loading...
Cat. No.: HY-172245
CAS No.: 2789697-52-3
Target:  

CDK

Research Areas:  

Cancer

Zeltociclib is a cyclin-dependent kinase inhibitor with antitumor effects .
loading...
    loading...
Cat. No.: HY-163170
CAS No.: 2741262-15-5
Target:  

CDK

Research Areas:  

Cancer

FMF-04-159-R is a cyclin-dependent kinase CDK14 and CDK16 inhibitor with IC50 values of 5.9 and 139.1 nM .
loading...
    loading...
Cat. No.: HY-108348
CAS No.: 267654-00-2
Purity:  99.12%
Target:  

CDK

Research Areas:  

Neurological Disease

BML-259 is a potent cyclin-dependent kinase 5 (Cdk5) inhibitor, with IC50s of 64 and 98 nM for Cdk5 and Cdk2, respectively .
loading...
    loading...
Cat. No.: HY-115565
CAS No.: 190653-73-7
Target:  

CDK Apoptosis

Research Areas:  

Cancer

CGP-74514 (Compound 13) is a highly selective cyclin-dependent kinase 1 (CDK1) inhibitor (IC50=25 nM). CGP-74514 inhibits CDK1/cyclin B complex activity, arrests the cell cycle at G2/M phase and induces tumor cell apoptosis. CGP-74514 is promising for research of bladder cancer .
loading...
    loading...